About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Anemia Drug Does Not Improve Health of Anemic Heart Failure Patients

by Sheela Philomena on March 11, 2013 at 11:37 AM
Font : A-A+

 Anemia Drug Does Not Improve Health of Anemic Heart Failure Patients

Darbepoetin alfa - a drug used to treat anemia in heart failure patients does not improve patients' death, finds study.

Results of the international study were presented at the American College of Cardiology's annual meeting in San Francisco on March 10 and published simultaneously online by the New England Journal of Medicine.

Advertisement

Initiated in 2006, the RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) trial involved 2,278 anemic heart failure patients at 453 sites in 33 countries. Patients were randomly given either darbepoetin alfa or placebo. In the darbepoetin alfa group, 50.7 percent of the patients experienced death from any cause or hospitalization for worsening heart failure. In the placebo group, 49.5 percent of the patients experienced similar clinical outcomes. The trial was funded by Amgen, the maker of darbepoetin alfa (trade name: Aranesp).

"This landmark study provides answers to caregivers who treat patients with heart failure complicated by anemia," said James Young, M.D., cardiologist and Chair of the Cleveland Clinic Endocrinology & Metabolism Institute, and co-investigator of the RED-HF trial. "Our findings do not support the use of darbepoetin alfa to treat anemic heart failure patients."
Advertisement

Anemia, the lack of red blood cells, is a common and serious problem in people who suffer from heart failure. It can lead to worse quality of life, higher rates of hospitalization and death. Treatment options have focused on correcting anemia with the use of intravenous iron or drugs that stimulate red blood cells.

"The benefits of erythropoietin-stimulating agents (ESAs) such as darbepoetin alfa to treat patients with heart failure and anemia have been questioned due to contradictory research findings," said Karl Swedberg, M.D., Ph.D., a senior professor at the Sweden-based Department of Medicine, Sahlgrenska University Hospital and co-investigator of the RED-HF trial. "Our study results show that the use of darbepoetin alfa to stimulate the production of red blood cells is an ineffective treatment for patients with heart failure and anemia."

According to the study, researchers found that darbepoetin alfa treatment led to an early and sustained increase in hemoglobin compared with placebo. However, darbepoetin alfa treatment did not reduce the risk of death from any cause or hospitalization from heart failure. Findings suggest that hemoglobin is a marker of poor prognosis in heart failure, rather than a therapeutic target. There were no new safety findings identified in the study. However, researchers observed an increased risk of thrombosis in the darbepoetin alfa group.

Researchers note that further research is needed to identify treatment options for this patient population.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Goji Berries May Protect Against Age-Related Vision Loss
Tapping — A Proven Self-Applied Stress Intervention
Black Pepper as Preventive Measure Against Omicron
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Anemia Drug Toxicity Rheumatic Fever Thalassemia Congenital Heart Disease Signature Drug Toxicity Heart Healthy Heart Anemia in Pregnancy Iron & Folate Deficiency Anemia In Pregnancy 

Recommended Reading
Aplastic Anemia
Aplastic anemia (AA) is a term that refers to a condition where the body fails to produce enough ......
Congestive Heart Failure
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump ...
Amgen Fined $762 Million Over Anemia Drug
American pharmaceutical company Amgen will have to pay a record $762 million fine after it pleaded ....
Anemia Drug, Eprex, Recalled by Johnson & Johnson
Johnson & Johnson has announced the recall of close to 200,000 syringes of Eprex, a drug used to ......
Anemia
Anemia is a condition in which the red blood cell (RBC) count or hemoglobin is less than normal....
Anemia in Pregnancy
Anemia is the commonest blood disorder that may occur in pregnancy and is usually due to low iron or...
Congenital Heart Disease
Heart diseases that are present at birth are called “ Congenital heart diseases”....
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Iron & Folate Deficiency Anemia In Pregnancy
About 95% of the anemia cases are due to iron deficiency....
Rheumatic Fever
Rheumatic fever is an inflammatory disease that may develop after an infection with group A Streptoc...
Thalassemia
Thalassemia is an inherited blood disorder passed on through parental genes causing the body to prod...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)